IP Library Granted Patent US 12,116,408
Granted Patent B2
US 12,116,408 · App. 17/380,404 · Granted Oct 15, 2024

Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity

Inventors: Anette Henriksen (Alleroed, DK); Kristian Kjaergaard (Ballerup, DK); Vibeke Westphal Stennicke (Kokkedal, DK); Charlotte Wiberg (Bjärred, SE)
Assignee: NOVO NORDISK A/S
C07K16/2803C07K2299/00C07K2317/55C07K2317/565C07K2317/76C07K2317/90C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,116,408
App. No.
17/380,404
Granted
Oct 15, 2024
Kind
B2
Abstract

Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Claims (13)

1. An antibody or fragment thereof that is capable of binding to and blocking TREM-1, wherein:

the antibody or fragment thereof has a viscosity of less than 5 cP at a concentration of 80 mg/mL; and

the antibody or fragment thereof comprises a variant of SEQ ID NO: 3 wherein at least one or both of E27 and E97 of the CDR1 and CDR3 regions of SEQ ID NO: 3 is substituted with an amino acid residue selected from the group consisting of glycine, alanine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.

2. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof has a viscosity of less than 4 cP at a concentration of 80 mg/mL.

3. The antibody or fragment thereof of claim 1 , wherein E27 of SEQ ID NO: 3 is substituted with glutamine and E97 is substituted with an amino acid selected from the group consisting of glycine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.

4. The antibody or fragment thereof of claim 3 , wherein E97 is substituted with an amino acid selected from the group consisting of serine and glutamine.

5. The antibody or fragment thereof of claim 1 , wherein E97 of SEQ ID NO: 3 is substituted with glutamine and E27 is substituted with an amino acid selected from the group consisting of glycine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.

6. The antibody or fragment thereof of claim 5 , wherein E27 is substituted with an amino acid selected from the group consisting of serine and glutamine.

7. The antibody or fragment thereof of claim 1 , wherein E27 of SEQ ID NO: 3 remains unmutated and E97 is substituted with an amino acid selected from the group consisting of glycine, alanine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.

8. The antibody or fragment thereof of claim 7 , wherein E97 is substituted with an amino acid selected from the group consisting of serine and glutamine.

9. The antibody or fragment thereof of claim 1 , wherein E27 and E97 of SEQ ID NO: 3 are both substituted with glutamine.

10. The antibody or fragment thereof of claim 1 , wherein E97 of SEQ ID NO: 3 remains unmutated and E27 is substituted with an amino acid selected from the group consisting of glycine, alanine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.

11. The antibody or fragment thereof of claim 10 , wherein E27 is substituted with an amino acid selected from the group consisting of serine and glutamine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2021
From: HENRIKSEN, ANETTE; KJAERGAARD, KRISTIAN; STENNICKE, VIBEKE WESTPHAL; WIBERG, CHARLOTTE
To: NOVO NORDISK A/S
Reel/Frame 056962/0694 →
Priority Claims (2)
EP 14177547 · Jul 17, 2014 · regional
EP 14194893 · Nov 26, 2014 · regional
Continuity (3)
Continuation 16203327 · Nov 28, 2018
Division 15325865
Related Publication 20220010012A1 · Jan 13, 2022